In today’s ACT Brief, we look at what’s fueling rapid growth in CNS and autoimmune research, why former FDA leaders are ...
Chen: Yes, obesity is experiencing accelerated growth over the last couple of years. According to our sister product Evaluate ...
AI-driven discovery, EHR-based real-world evidence, and synthetic patient modeling are rapidly reshaping drug repurposing, reducing development timelines, expanding therapeutic applications, and ...
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
In their NEJM commentary, the former FDA heads stated, “We are deeply concerned by sweeping new FDA assertions about vaccine safety and proposals that would undermine a regulatory model designed to ...
In today’s ACT Brief, we look at new insights on strategy-driven clinical development, fresh survey data revealing persistent ...
For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...
Examine the rise of personalized and biomarker-driven therapies, the logistical challenges of rare patient populations, and ...
The FDA has launched a secure, GovCloud-based agentic AI system to support regulatory workflows across review divisions, ...
In today’s ACT Brief, we examine how the FDA’s CNPV Program is reshaping operational planning and accelerated submission ...
In today’s ACT Brief, we examine how the CRA role is transforming alongside modern clinical trial technology, review the ...
ICON’s June 2025 survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and ...
With the right technology and support, CRAs can continue their evolution into powerful agents of trial success that bridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback